Prime driver for global diabetes management market is increasing incidence of type I and type II diabetes combined with high obese population. Additionally, combination therapy as compared to monotherapy is gaining popularity due to its high efficacious nature. Increase in collaborations and alliances are the better avenues to attain high profitability. However, global diabetes management market suffers from some of the critical restrains namely, counterfeiting of drugs, scarcity of healthcare personnel in some countries such as Russia, cost sensitivity and limited infrastructure for management. Emerging economies offer ample opportunities to big players of this market to expand their business. Also, there is a need of improved, efficacious and safe treatment, which can be fulfilled by innovative R&D.
Global Diabetes Management Market by Device Type
The diabetes management market is segmented by type of devices into monitoring, diagnostic, insulin delivery and other devices. Blood glucose monitoring devices has the largest market share, as critical monitoring of glucose level is necessary for the management of diabetes. Also, the insulin delivery devices have increased its sale to promising value, which has resulted in improvement in insulin delivery technology. In this segment, insulin pens are more popular as they are less painful in usage.
Global Diabetes Management Market by Therapeutics
The global diabetes management market is segmented by therapeutics into two broad categories, namely injectables and orally administered drugs. Therapeutic segment as a whole is largely dominated by human insulin and its analogues. Currently, dipeptidyl inhibitors has boosted the market growth and generated high revenue due to its safe nature and once daily dose regimen. Strong R&D pipeline has lead to development of safe and efficacious drugs, which has further fueled the market growth.
Global Diabetes Management Market by Geography
Geographically, diabetes management market is segmented into North America, Europe, Asia and LAMEA. North America and Asia-pacific dominates diabetes management market due to high incidences of diabetes and large pool of aging population. Currently, China is evolving as one of the major pharma market for diabetes care and management. The reasons studied are robust economic growth, ageing population and sweeping healthcare reforms.
The leading companies in global diabetes management market include Abbott Laboratories, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Co., Sanofi, Dexcom, Medtronic and Novo Nordisk A/S. Currently, Abbott, Dexcom and Medtronic dominate continuous glucose monitoring devices market and have launched several new product
* This report will be delivered in 12 Business Days. *